1834 Investment Advisors Co. Has $8.46 Million Stake in Johnson & Johnson (NYSE:JNJ)

1834 Investment Advisors Co. decreased its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 9.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,481 shares of the company’s stock after selling 5,732 shares during the period. Johnson & Johnson accounts for 1.0% of 1834 Investment Advisors Co.’s investment portfolio, making the stock its 24th biggest holding. 1834 Investment Advisors Co.’s holdings in Johnson & Johnson were worth $8,460,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Granite Harbor Advisors Inc. boosted its position in shares of Johnson & Johnson by 5.9% during the 3rd quarter. Granite Harbor Advisors Inc. now owns 6,609 shares of the company’s stock valued at $1,029,000 after acquiring an additional 366 shares in the last quarter. Kampmann Melissa S. bought a new stake in Johnson & Johnson in the third quarter valued at $3,674,000. Tompkins Financial Corp lifted its holdings in shares of Johnson & Johnson by 1.4% during the third quarter. Tompkins Financial Corp now owns 33,823 shares of the company’s stock valued at $5,268,000 after acquiring an additional 461 shares during the period. Carlson Capital Management boosted its position in Johnson & Johnson by 1.4% in the third quarter. Carlson Capital Management now owns 13,912 shares of the company’s stock valued at $2,167,000 after buying an additional 187 shares in the last quarter. Finally, Allen Mooney & Barnes Investment Advisors LLC acquired a new stake in Johnson & Johnson during the 3rd quarter valued at $1,341,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.5 %

Shares of Johnson & Johnson stock opened at $146.48 on Monday. The stock has a market cap of $352.53 billion, a P/E ratio of 9.13, a P/E/G ratio of 2.44 and a beta of 0.52. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The business’s 50 day moving average is $147.94 and its 200-day moving average is $153.72. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. Johnson & Johnson’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.68 EPS. Equities research analysts predict that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.39%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research analyst reports. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. Bank of America lowered their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research note on Monday, June 17th. Finally, Morgan Stanley lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Eight investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $174.07.

View Our Latest Report on JNJ

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.